Headlines about Psychemedics (NASDAQ:PMD) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Psychemedics earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave news articles about the company an impact score of 47.4012977706623 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Psychemedics opened at $20.70 on Friday, MarketBeat Ratings reports. The firm has a market cap of $112.64 million, a PE ratio of 23.85 and a beta of 0.75. The company has a current ratio of 3.01, a quick ratio of 3.01 and a debt-to-equity ratio of 0.11. Psychemedics has a 12-month low of $15.99 and a 12-month high of $27.99.
Psychemedics (NASDAQ:PMD) last announced its earnings results on Wednesday, March 7th. The company reported $0.22 earnings per share (EPS) for the quarter. The company had revenue of $9.76 million for the quarter. Psychemedics had a return on equity of 26.72% and a net margin of 14.52%.
Psychemedics Company Profile
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time.
Receive News & Ratings for Psychemedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psychemedics and related companies with MarketBeat.com's FREE daily email newsletter.